Search Advanced

Mathematical Biosciences and Engineering

2016, Volume 13, Issue 6: 1185-1206. doi: 10.3934/mbe.2016038
Previous Article Next Article

Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases

  • 1.
    Department of Biology, The College of New Jersey, Ewing, NJ
  • 2.
    Integrated Mathematical Oncology Department and Center of Excellence in Cancer Imaging and Technology, H. Lee Mott Cancer Center and Research Institute, Department of Oncologic Sciences, University of South Florida, Tampa, FL
  • 3.
    Department of Mathematics and Statistics, The College of New Jersey, Ewing, NJ
  • Received: 01 October 2015 Accepted: 29 June 2018 Published: 01 August 2016

  • MSC : Primary: 92C50; Secondary: 37N25.

  • While chemoresistance in primary tumors is well-studied, much less is known about the influence of systemic chemotherapy on the development of drug resistance at metastatic sites. In this work, we use a hybrid spatial model of tumor response to a DNA damaging drug to study how the development of chemoresistance in micrometastases depends on the drug dosing schedule. We separately consider cell populations that harbor pre-existing resistance to the drug, and those that acquire resistance during the course of treatment. For each of these independent scenarios, we consider one hypothetical cell line that is responsive to metronomic chemotherapy, and another that with high probability cannot be eradicated by a metronomic protocol. Motivated by experimental work on ovarian cancer xenografts, we consider all possible combinations of a one week treatment protocol, repeated for three weeks, and constrained by the total weekly drug dose. Simulations reveal a small number of fractionated-dose protocols that are at least as effective as metronomic therapy in eradicating micrometastases with acquired resistance (weak or strong), while also being at least as effective on those that harbor weakly pre-existing resistant cells. Given the responsiveness of very different theoretical cell lines to these few fractionated-dose protocols, these may represent more effective ways to schedule chemotherapy with the goal of limiting metastatic tumor progression.

    Citation: Ami B. Shah, Katarzyna A. Rejniak, Jana L. Gevertz. Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases[J]. Mathematical Biosciences and Engineering, 2016, 13(6): 1185-1206. doi: 10.3934/mbe.2016038

    Related Papers:

  • While chemoresistance in primary tumors is well-studied, much less is known about the influence of systemic chemotherapy on the development of drug resistance at metastatic sites. In this work, we use a hybrid spatial model of tumor response to a DNA damaging drug to study how the development of chemoresistance in micrometastases depends on the drug dosing schedule. We separately consider cell populations that harbor pre-existing resistance to the drug, and those that acquire resistance during the course of treatment. For each of these independent scenarios, we consider one hypothetical cell line that is responsive to metronomic chemotherapy, and another that with high probability cannot be eradicated by a metronomic protocol. Motivated by experimental work on ovarian cancer xenografts, we consider all possible combinations of a one week treatment protocol, repeated for three weeks, and constrained by the total weekly drug dose. Simulations reveal a small number of fractionated-dose protocols that are at least as effective as metronomic therapy in eradicating micrometastases with acquired resistance (weak or strong), while also being at least as effective on those that harbor weakly pre-existing resistant cells. Given the responsiveness of very different theoretical cell lines to these few fractionated-dose protocols, these may represent more effective ways to schedule chemotherapy with the goal of limiting metastatic tumor progression.


    加载中
    [1] Mol. Biotechnol., 46 (2010), 308-316.
    [2] Journal of Theoretical Biology, 335 (2013), 235-244.
    [3] eLife, 2 (2013), e00747.
    [4] Curr. Breast Cancer Rep., 6 (2014), 110-120.
    [5] Lung Cancer, 54 (2006), 353-357.
    [6] J. Cellular Physiol., 151 (1992), 386-394.
    [7] Bull. Math. Biol., 48 (1986), 279-292.
    [8] Evolution, Medicine, and Public Health, 2015 (2015), 76-87.
    [9] Mol. Pharm., 8 (2011), 2094-2100.
    [10] Mol. Cancer Ther., 10 (2011), 1289-1299.
    [11] Neoplasia, 13 (2011), 40-48.
    [12] Evol. Appl., 6 (2013), 54-69.
    [13] PLoS Comput. Biol., 5 (2009), e1000557, 17pp.
    [14] J. Theor. Biol., 263 (2010), 179-188.
    [15] J. Theor. Biol., 355 (2014), 10-20.
    [16] J. Cellular Physiol., 124 (1985), 516-524.
    [17] PLoS Comput. Biol., 11 (2015), e1004142.
    [18] Cancer Res., 69 (2009), 4894-4903.
    [19] in Applications of Dynamical Systems in Biology and Medicine (eds. T. Jackson and A. Radunskaya), vol. 158 of The IMA Volumes in Mathematics and its Applications, Springer-Verlag, 2015, 1-34.
    [20] Bull. Math. Biol., 76 (2014), 627-653.
    [21] IEEE Trans. Biomed. Eng., 61 (2013), 415-425.
    [22] The Journal of Clinical Investigations, 105 (2000), 1045-1047.
    [23] Math. Biosci., 164 (2000), 17-38.
    [24] Nat. Rev. Cancer, 5 (2005), 516-525.
    [25] Proc. Natl. Acad. Sci., 102 (2005), 9714-9719.
    [26] Theor. Popul. Biol., 72 (2007), 523-538.
    [27] Drug Resist. Update, 15 (2012), 90-97.
    [28] Cancer Res., 73 (2013), 7168-7175.
    [29] Mathematical Biosciences and Engineering, 12 (2015), 1257-1275.
    [30] Discret. Contin. Dyn-B, 6 (2006), 129-150.
    [31] Math. Biosci. Eng., 10 (2013), 803-819.
    [32] Bull. Math. Biol., 77 (2015), 1-22.
    [33] ESAIM: Math. Model. Num. Anal., 47 (2013), 377-399.
    [34] Front. Oncol., 4 (2014), article 76.
    [35] Cell Prolif., 34 (2001), 253-266.
    [36] Acta Biother., 63 (2015), 113-127.
    [37] Journal of Cancer Therapeutics & Research, 1 (2012), 1-32.
    [38] Mol. Pharm., 8 (2011), 2069-2079.
    [39] Current Oncology, 16 (2012), 7-15.
    [40] Phys. Biol., 9 (2012), 065007.
    [41] J. Clinical Oncology, 23 (2005), 939-952.
    [42] Br. J. Cancer, 112 (2015), 1725-1732.
    [43] arXiv:1407.0865.
    [44] Molecular Oncology, 7 (2013), 283-296.
    [45] Biol. Direct., 5 (2010), p25.
    [46] J. Natl. Cancer Inst., 99 (2007), 1441-1454.
    [47] Assay Drug Dev Technol., 3 (2005), 525-531.
    [48] International Journal of Cancer, 133 (2013), 2464-2472.
    [49] Nature, 525 (2015), 261-264.
    [50] Proc. Natl. Acad. Sci., 110 (2013), 16103-16108.
    [51] Front. Pharmacol., 4 (2013), e28.<br/
  • Reader Comments
  • © 2016 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Mathematical Biosciences and Engineering
3.9

Metrics

Article views(2225) PDF downloads(472) Cited by(17)

Preview PDF
Download XML
Export Citation
Article outline

Other Articles By Authors

Related pages

Tools

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog